CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Clinical trials for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) explained in plain language.
Never miss a new study
Get alerted when new CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS) trials appear
Sign up with your email to follow new studies for CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New study tracks ilaris for rare fever diseases in kids and adults
Disease control Recruiting nowThis study watches how well the drug Ilaris works and how safe it is for children and adults with rare hereditary fever syndromes (like CAPS, FMF, TRAPS, HIDS/MKD) and a type of childhood arthritis called sJIA. About 25 people will be followed during their regular treatment. The …
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:59 UTC
-
New CAPS pill shows promise in tiny early trial
Disease control Recruiting nowThis study tests an experimental drug called JTE-162 in 5 adults with CAPS, a rare genetic disease that causes fever, rash, and joint pain. Participants take one pill daily for 2 weeks. Researchers will check if the drug reduces inflammation and symptoms safely. This is an early-…
Matched conditions: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
Phase: PHASE1 • Sponsor: Akros Pharma Inc. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC